GLUE

5.71

4.19% -0.25

Dopo l'orario di chiusura: 5.70 -0.010 -0.18%

Monte Rosa Therapeutics Inc (GLUE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GLUE Giù? Forum Previsione

Precedente Chiudi:

$5.96

Aprire:

$5.92

Volume 24 ore:

479.46K

Relative Volume:

1.08

Capitalizzazione di mercato:

$351.22M

Reddito:

Utile/perdita netta:

$-130.41M

Rapporto P/E:

-2.5491

EPS:

-2.24

Flusso di cassa netto:

$-67.76M

1 W Prestazione:

-3.22%

1M Prestazione:

+20.46%

6M Prestazione:

+3.44%

1 anno Prestazione:

+29.77%

Intervallo 1D:

$5.64

$5.92

Intervallo di 1 settimana:

$5.4529

$6.25

Portata 52W:

$3.5001

$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Nome

Monte Rosa Therapeutics Inc

Settore

Healthcare (1161)

Industria

Biotechnology (651)

Telefono

617-949-2643

Indirizzo

321 HARRISON AVENUE, BOSTON

Dipendente

134

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

GLUE's Discussions on Twitter

Confronta GLUE con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GLUE Monte Rosa Therapeutics Inc	5.71	366.60M	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-02-15	Iniziato	Wedbush	Outperform
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-13	Iniziato	UBS	Buy
2022-08-15	Iniziato	Jefferies	Buy
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-02-10	Iniziato	Wells Fargo	Equal Weight
2021-10-14	Iniziato	SVB Leerink	Mkt Perform

Mostra tutto

Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie

Jul 24, 2025

What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional

Jul 24, 2025

Jul 23, 2025

What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional

Jul 23, 2025

Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire

Jul 21, 2025

Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest

Jul 21, 2025

Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com

Jul 21, 2025

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewswire

Jul 21, 2025

First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan

Jul 21, 2025

Jul 18, 2025

Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest

Jul 18, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st

Jul 18, 2025

Jul 17, 2025